Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening.
Ontology highlight
ABSTRACT: Experiments with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are limited by the need for biosafety level 3 (BSL3) conditions. A SARS-CoV-2 replicon system rather than an in vitro infection system is suitable for antiviral screening since it can be handled under BSL2 conditions and does not produce infectious particles. However, the reported replicon systems are cumbersome because of the need for transient transfection in each assay. In this study, we constructed a bacterial artificial chromosome vector (the replicon-BAC vector) including the SARS-CoV-2 replicon and a fusion gene encoding Renilla luciferase and neomycin phosphotransferase II, examined the antiviral effects of several known compounds, and then established a cell line stably harboring the replicon-BAC vector.
SUBMITTER: Tanaka T
PROVIDER: S-EPMC8900913 | biostudies-literature | 2022 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA